ParkerVision (PRKR) 10-K 29 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 28, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Entity Registrant Name	PARKERVISION INC
Entity Central Index Key	914,139
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Common Stock, Shares Outstanding		23,806,746
Entity Public Float			$ 30,366,337
Trading Symbol	prkr
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 354	$ 258
Restricted cash equivalents	1,000	911
Available-for-sale securities	26	14
Accounts receivable, net of allowance for doubtful accounts of $3 and $4 at December 31, 2017 and 2016, respectively	27	1
Inventories, net	1,025	170
Prepaid expenses and other	1,011	685
Total current assets	3,443	2,039
Property and equipment, net	376	269
Intangible assets, net	5,076	6,268
Other assets, net	15
Total assets	8,910	8,576
CURRENT LIABILITIES:
Accounts payable	678	595
Accrued expenses:
Salaries and wages	376	297
Professional fees	2,054	455
Other accrued expenses	225	267
Note payable, current portion	294	825
Deferred rent, current portion	13	51
Deferred revenue	19	19
Total current liabilities	3,659	2,509
LONG-TERM LIABILITES:
Capital lease, net of current portion	2
Deferred rent, net of current portion	66	1
Note payable, net of current portion	531
Secured contingent payment obligation	15,896	14,185
Total long-term liabilities	16,495	14,186
Total liabilities	20,154	16,695
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' (DEFICIT) EQUITY:
Common stock, $.01 par value, 30,000 shares authorized, 21,222 and 13,183 issued and outstanding at December 31, 2017 and 2016, respectively	212	132
Warrants outstanding	826	826
Additional paid-in capital	359,141	343,087
Accumulated deficit	(371,423)	(352,164)
Total shareholders' (deficit) equity	(11,244)	(8,119)
Total liabilities and shareholders' (deficit) equity	$ 8,910	$ 8,576

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Thousands	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Consolidated Balance Sheets [Abstract]
Accounts receivable, net of allowance for doubtful accounts | $	$ 3	$ 4
Common stock, par value | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	21,222,000	13,183,000
Common stock, shares outstanding	21,222,000	13,183,000

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements Of Comprehensive Loss [Abstract]
Licensing revenue		$ 4,000
Product and services revenue	100	64
Total revenue	100	4,064
Cost of sales - licensing		301
Cost of sales - product and service	75	41
Writedown of obsolete inventory	125
Gross margin	(100)	3,722
Research and development expenses	4,344	3,343
Selling, general and administrative expenses	14,061	16,318
Total operating expenses	18,405	19,661
Interest and other income	26	18
Interest expense	(69)	(68)
Change in fair value of contingent payment obligation (Note 8)	(711)	(4,860)
Total interest and other	(754)	(4,910)
Net loss before income taxes	(19,259)	(20,849)
Foreign income tax expense		(660)
Net loss	(19,259)	(21,509)
Other comprehensive income (loss), net of tax
Comprehensive loss	$ (19,259)	$ (21,509)
Basic and diluted net loss per common share	$ (1.09)	$ (1.76)
Weighted average common shares outstanding	17,688	12,244

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders (Deficit) Equity - USD ($) $ in Thousands	Common Stock [Member]	Warrants Outstanding [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 110	$ 1,300	$ 335,528	$ (330,655)	$ 6,283
Issuance of common stock and warrants in public and private offerings	16	335	3,785		4,136
Issuance of common stock upon exercise of options and warrants	1	(912)	1,333		422
Issuance of common stock for services	3		427		430
Share-based compensation, net of shares withheld for taxes	2	103	2,014		2,119
Comprehensive income (loss) for the year				(21,509)	(21,509)
Balance at Dec. 31, 2016	132	826	343,087	(352,164)	(8,119)
Issuance of common stock and warrants in public and private offerings	73		13,606		13,679
Issuance of common stock for services	3		422		425
Share-based compensation, net of shares withheld for taxes	4		2,026		2,030
Comprehensive income (loss) for the year				(19,259)	(19,259)
Balance at Dec. 31, 2017	$ 212	$ 826	$ 359,141	$ (371,423)	$ (11,244)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,259)	$ (21,509)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,301	1,375
Share-based compensation	2,164	2,210
Loss on disposal of equipment and other assets	85	257
Writedown of obsolete inventory	125
Realized (gain) loss on available-for-sale securities	(9)	1
Changes in fair value of contingent payment obligation	711	4,860
Changes in operating assets and liabilities:
Accounts receivable	(26)	3
Inventories	(980)	1
Prepaid expenses and other	84	(33)
Accounts payable and accrued expenses	1,717	(1,453)
Deferred rent	27	(74)
Deferred revenue		(2)
Total adjustments	5,199	7,145
Net cash used in operating activities	(14,060)	(14,364)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of available-for-sale securities	(4,813)	(4,405)
Proceeds from redemption of available-for-sale securities	4,810	6,180
Proceeds from sale of assets	18
Purchases of property and equipment	(252)	(6)
Payments for patent costs and other intangible assets	(61)	(153)
Net cash (used in) provided by investing activities	(298)	1,616
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock in public and private offerings	13,679	3,801
Net proceeds from exercise of options and warrants		422
Shares withheld for payment of taxes	(134)	(90)
Proceeds from contingent payment obligation	1,000	13,000
Repayment of contingent payment obligation		(3,340)
Principal payments on capital lease obligation	(2)	(52)
Net cash provided by financing activities	14,543	13,741
NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS	185	993
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, beginning of year	1,169	176
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, end of year	1,354	1,169
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	69	62
Cash paid for income taxes		$ 660
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES:
Purchase of equipment under capital lease (Note 6)	$ 6

The Company And Nature Of Busin

The Company And Nature Of Business	12 Months Ended
	Dec. 31, 2017
The Company And Nature Of Business [Abstract]
The Company And Nature Of Business	1. THE COMPANY AND NATURE OF BUSINESS  ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware and software technologies and products. We have designed and developed a consumer distributed WiFi product line that is being marketed under the brand name Milo ® . We also design and develop our proprietary radio frequency (“RF”) technologies for use in semiconductor circuits for wireless communication products. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore our business plan includes enforcement of our intellectual property rights through patent infringement litigation and licensing efforts . We have determined that our business currently operates under a single operating and reportable segment.

Liquidity And Going Concern

Liquidity And Going Concern	12 Months Ended
	Dec. 31, 2017
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern	2. LIQUIDITY AND GOING CONCERN  The accompanying consolidated financial statements as of and for the year ended December 31, 2017 were prepared assuming we will continue as a going concern, which contemplates that we will continue in operation and will be able to realize our assets and settle our liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these financial statements. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.  We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity securities and our contingent funding arrangements with third-parties to fund our operations, including our litigation costs. For the year ended December 31, 2017, we incurred a net loss of approximately $19. 3 million and negative cash flows from operations of approximately $14. 1 million. At December 31, 2017, we had a working capital deficit of approximately $0.2 million and an accumulated deficit of approximately $3 71.4 million. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year after the issuance date of these consolidated financial statements.  At December 31, 2017, we had cash, cash equivalents and available for sale securities of approximately $0.4 million and restricted cash equivalents of $1.0 million. Additionally, we began shipments of our WiFi networking product line in October 2017. Although we anticipate growth in revenues and margin generated by this product line will reduce our net losses in 2018, sales of our WiFi product line will not be sufficient to fund our operations without the need for additional working capital. In addition, although we may receive proceeds from our patent enforcement actions in 2018, the timing and amount of such proceeds, if any, are difficult to predict and there can be no assurance we will receive any proceeds from these enforcement actions.  Our ability to meet our liquidity needs for the twelve months after the issuance date is dependent upon one or more of (i) our ability to develop, market and sell existing and new products; (ii) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations to BKI and legal counsel; and/or (iii) our ability to raise additional capital from the sale of equity securities or other financing arrangements. We anticipate that we will continue to invest in patent protection, research and development, and production, selling and marketing of our WiFi networking product line. We expect that revenue generated from product sales, patent enforcement actions, and technology licenses over the twelve months after the issuance date will not be sufficient to cover our operating expenses. In the event we do not generate revenues, or other patent-asset proceeds, sufficient to cover our operational costs and contingent repayment obligation, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements.  We are pursuing a two to three year financing transaction with third parties that may include debt, equity, in the form of common and preferred stock, or a combination thereof. There can be no assurance that we will be able to consummate a financing transaction with any of these third parties or that the terms of any such financing will be on terms and conditions that are acceptable. Until such time that we are able to consummate a longer-term financing transaction, we will continue to use the capacity available under our ATM and our common stock purchase agreement with Aspire to fund our short-term operations. The capital available to us under those financing vehicles is limited based on the remaining amounts available under our Shelf and limitations under Nasdaq rules with regards to the issuance of shares in excess of 19.99% of pre-transaction shares outstanding (see Note 11).  The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles. Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH after elimination of all intercompany transactions and accounts.  Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.  Cash, Cash Equivalents, and Restricted Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased. Restricted cash equivalents represent money market investments that are restricted for specific use in payment of legal fees and expenses related to certain of our patent infringement actions. The restricted money market investments have weighted average maturities of three months or less when purchased and are recorded at fair value. We have determined that the fair value of our restricted money market investments fall within Level 1 in the fair value hierarchy (see Note 16).  Available-for-Sale Securities A vailable-for-sale securities are intended to be held for indefinite periods of time and are not intended to be held to maturity. These securities are recorded at fair value and any unrealized holding gains and losses, net of the related tax effect, are excluded from earnings and are reported as a separate component of accumulated other comprehensive loss until realized. The tax effect of our unrealized holding gains and losses is zero for each of the years ended December 31, 2017 and 2016 due to the existence of a full valuation allowance. Our available-for-sale securities at December 31, 2017 and 2016 consisted of mutual funds that invest primarily in short-term municipal securities with an average effective maturity of one year or less. All dividends and realized gains are recognized as other income as earned and immediately reinvested. The Company has determined that the fair value of its available-for-sale securities fall within Level 1 in the fair value hierarchy (See Note 16).  Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change. For the year ended December 31, 2017, we recognized a write down of excess inventory of our PV5870 ICs of approximately $0.1 million.  Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:      Manufacturing and office equipment 5 -7 years  Tooling 3 years  Leasehold improvements Remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.  Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. We estimate the economic lives of other intangible assets, including licenses, based on estimated technological obsolescence, to be two to five years, which is generally shorter than the contractual lives. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.  Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 16). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation”.  Leases Our facilities are leased under operating leases. For those leases that contain rent escalations or rent concessions, we record the total rent payable during the lease term on a straight-line basis over the term of the lease with the difference between the rents paid and the straight-line rent recorded as a deferred rent liability in the accompanying consolidated balance sheets.  In February 2016, the FASB issued ASU 2016-02 “Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption of ASU 2016-02, beginning period balances for the earliest period presented must be adjusted to reflect the re-measurement of lease assets and liabilities. We anticipate adoption of ASU 2016-02 as of January 1, 2019. We have identified all existing operating and financing leases and are in the process of determining the present value of existing lease assets and liabilities under the new guidance. We are also currently formalizing processes and controls to identify, classify and measure new leases in accordance with ASU 2016-02. The impact of ASU 2016-02 on our consolidated financial statements is currently being evaluated.  Revenue Recognition We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes, sales of products, and engineering services. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when there is persuasive evidence of an arrangement, title has transferred, the amounts are fixed and determinable and the collectability is reasonably assured.   Revenue from the sale of products is recognized at the time of shipment to the customer or when the other criteria for revenue recognition are met, if later. Unearned revenue at December 31, 2017 and 2016 consists of product inventory held by a distributor. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when earned. We recognize revenues upon execution of a patent license and settlement agreement by both parties provided that the amounts are fixed and determinable, there are no significant undelivered obligations and collectability is reasonably assured. We do not recognize any revenue prior to the execution of an agreement as there is no reliable basis on which we can estimate the amounts related to the elements of the arrangement, or assess collectability. In addition, we do not recognize as revenue any consideration in the agreement that is contingent upon the occurrence of future events until such time that those future events occur.  In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. ASU 2015-14, “Revenue from Contracts with Customers (Topic 606)”, issued in August 2015, defers adoption of ASU 2014-09 to annual reporting periods beginning after December 15, 2017. We do not currently expect the adoption of ASU 2014-09 to have a material effect on our consolidated financial statements .  Shipping and Handling Costs Shipping and handling costs related to product sales were approximately $5,000 , or 5% of product revenue, for the year ended December 31, 2017. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.4 million and $0 for the years ended December 31, 2017 and 2016, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation.  Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 10. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The new standard is effective for annual periods beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. The adoption of this guidance is not expected to have a material effect on our consolidated financial statements.  Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease to 21% effective for tax years beginning after December 31, 2017.  Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  Options and warrants to purchase 1.4 million and 1.1 million shares of common stock were outstanding at December 31, 2017 and, 2016, respectively. In addition, unvested RSUs representing 0.5 million and 0.3 million shares of common stock were outstanding at December 31, 2017 and 2016, respectively. These options, warrants and RSUs were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventories [Abstract]
Inventories	4. INVENTORIES  Inventories consisted of the following at December 31, 2017 and 2016 (in thousands):     2017 2016  Raw materials $ 573 $ -  Work-in-process - 126  Finished goods 452 44  $ 1,025 $ 170 

Prepaid Expenses And Other

Prepaid Expenses And Other	12 Months Ended
	Dec. 31, 2017
Prepaid Expenses And Other [Abstract]
Prepaid Expenses And Other	5. PREPAID EXPENSES AND OTHER  Prepaid expenses and other current assets consisted of the following at December 31, 2017 and 2016 (in thousands):     2017 2016  Prepaid services $ 328 $ 459  Prepaid licenses, software tools and support 404 41  Prepaid inventory and production tooling 121 -  Prepaid insurance 54 108  Other prepaid expenses and current assets 104 77  $ 1,011 $ 685 

Property And Equipment, Net

Property And Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property And Equipment, Net [Abstract]
Property And Equipment, Net	6. PROPERTY AND EQUIPMENT, NET  Property and equipment, at cost, consisted of the following at December 31, 2017 and 2016 (in thousands):    2017 2016  Equipment and software, including equipment purchased under capital leases of $297 and $292 at December 31, 2017 and 2016, respectively $ 6,556 $ 7,777  Tooling - 94  Leasehold improvements 786 926  Furniture and fixtures 185 502  7,527 9,299  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $206 and $156 at December 31, 2017 and 2016, respectively (7,151) (9,030)  $ 376 $ 269   Depreciation expense related to property and equipment was approximately $0.15 million and $0.17 million in 2017 and 2016, respectively. Depreciation expense includes depreciation related to capital leases of approximately $0.05 million and $0.06 for the periods ended December 31, 2017 and 2016, respectively.  Our capital leases have original terms of one to three years. The principal payments for these capital leases are reflected as cash outflows from financing activities in the accompanying consolidated statements of cash flows. Future minimum lease payments under our capital leases that have initial terms in excess of one year are included in “Contractual Obligations” in Note 13.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Intangible Assets [Abstract]
Intangible Assets	7. INTANGIBLE ASSETS  Intangible assets consisted of the following at December 31, 2017 and 2016 (in thousands):    2017  Gross Carrying Amount Accumulated Amortization Net Value  Patents and copyrights $ 19,324 $ 14,248 $ 5,076  Licenses - - -  $ 19,324 $ 14,248 $ 5,076       2016  Gross Carrying Amount Accumulated Amortization Net Value  Patents and copyrights $ 19,499 $ 13,231 $ 6,268  Licenses 574 574 -  $ 20,073 $ 13,805 $ 6,268   Amortization expense for each of the years ended December 31, 2017 and 2016 was approximately $1.2 million.  Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2017 is as follows (in thousands):     2018 $ 1,062  2019 771  2020 546  2021 468  2022 417  2023 and thereafter 1,812  Total $ 5,076 

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2017
Long-Term Debt [Abstract]
Long-Term Debt	8. LONG-TERM DEBT  Note Payable to a Related Party The note payable to a related party at December 31, 2017 and 2016, consisted of the following (in thousands):      Description Interest Rate Interest Payable Maturity Date 2017 2016  Note payable to a related party 8% Monthly March 31, 2020 $ 825 $ 825  Less current maturities 294 825  Long-term note payable $ 531 $ -   In February 2016, we entered into an agreement with a related party (see Note 14) to convert $0.8 million in outstanding unpaid fees into an unsecured promissory note. The balance of the note was scheduled to mature on December 31, 2017 . In January 2018, we amended the note, retroactive to December 31, 2017 to allow for interest only payments through March 2018 and principle and interest payments through March 31, 2020.   Failure to comply with the payment terms of this note constitutes an event of default which, if uncured, will result in the entire unpaid principal balance of the note and any unpaid, accrued interest to become immediately due and payable. As of December 31, 2017, we are in compliance with the payment terms of the note.  At December 31, 2017, the aggregate maturities of our note payable to a related party are as follows (in thousands):     2018 $ 294  2019 420  2020 111  Total $ 825   The estimated fair value of our note payable at December 31, 2017 is approximately $0.7 million based on a risk-adjusted discount rate.  Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the year ended December 31, 2017 and 2016, respectively (in thousands).       2017 2016  Secured contingent payment obligation, beginning of year $ 14,185 $ -  Proceeds from contingent payment obligation 1 1,000 12,665  Repayment - (3,340)  Change in fair value 711 4,860  Secured contingent payment obligation, end of year $ 15,896 $ 14,185  1 Proceeds in 2016 are net of $0.3 million which represents the estimated fair market value of warrants issued in connection with the agreement (see Note 11).  Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments (“BKI”) under a February 2016 funding agreement, as amended in May 2016 and December 2017. Under the agreement, we received aggregate proceeds of $14 million in exchange for BKI’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions.  BKI is entitled to priority payment of 100% of proceeds received from all patent-related actions until such time that BKI has been repaid in full. After repayment of the funded amount, BKI is entitled to a portion of remaining proceeds up to a specified minimum return which is determined as a percentage of the funded amount and varies based on the timing of repayment. In addition, BKI is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the specified minimum return.  BKI holds a senior security interest in our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions. The security interest is enforceable by BKI in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to BKI, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without BKI’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under the agreement. As of December 31, 2017, we are in compliance with our obligations under this agreement.  We have elected to measure our secured contingent payment obligation at fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 16). The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved.

Income Taxes And Tax Status

Income Taxes And Tax Status	12 Months Ended
	Dec. 31, 2017
Income Taxes And Tax Status [Abstract]
Income Taxes And Tax Status	9. INCOME TAXES AND TAX STATUS  Our net losses before income taxes for the years ended December 31, 2017 and 2016 are from domestic operations as well as losses from our wholly-owned German subsidiary. We elected to treat our German subsidiary as a disregarded entity for purposes of income taxes and accordingly, the losses from our German subsidiary has been included in our operating results.  We recorded $0.7 million in current foreign income tax expense for the year ended December 31, 2016 as a result of foreign tax withholding on licensing revenues from a Korean entity. No current or deferred tax provision or benefit was recorded for 2017 and 2016 as a result of current losses and fully deferred tax valuation allowances for all periods. We have recorded a valuation allowance to state our deferred tax assets at their estimated net realizable value due to the uncertainty related to realization of these assets through future taxable income. On December 22, 2017, the U.S. government enacted comprehensive tax legislation, the Tax Act. The Tax Act makes broad and complex changes to the U.S. tax code that includes a reduction to the U.S. federal corporate statutory tax rate to 21% effective in 2018. As of December 31, 2017, our accounting for the income tax effects of the Tax Act has been completed. The federal corporate tax rate reduction creates a reduction to our deferred tax assets and liabilities with a corresponding reduction to our valuation allowance.  A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 34 % for the years ended December 31, 2017 and 2016 are as follows (in thousands):     2017 2016  Tax benefit at statutory rate $ (6,548) $ (7,313)  State tax benefit (674) (753)  Impact of the Tax Act 41,646 -  (Decrease) increase in valuation allowance (34,346) 8,145  Research and development credit (129) (97)  Other 51 18  $ - $ -   Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2017 and 2016 (in thousands):      2017 2016  Gross deferred tax assets:  Net operating loss carry-forward $ 82,168 $ 115,296  Research and development credit 8,051 7,922  Stock compensation 1,248 1,885  Patents and other 1,427 2,119  Contingent payment obligation 1,409 1,823  Fixed assets 25 78  Accrued liabilities 49 54  Deferred rent 20 19  Charitable contributions 7 11  Deferred revenue 5 7  Capital loss carry-forward 3 8  Warranty reserve 2 -  Bad debt expense 1 2  Inventory - 1  94,415 129,225  Less valuation allowance (94,415) (129,225)  Net deferred tax asset $ - $ -   At December 31, 2017, we had cumulative NOL, research and development (“R&D”) tax credit carry-forwards and ca pital loss carry-forwards for income tax purposes of $328.4 million, $8.1 million and $0.01 million, respectively , which expire in varying amounts from 2018 through 2036 .  Our ability to benefit from the our tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if our ownership changes by more than 50%, as defined by Section 382 of the Internal Revenue Code of 1986 (“Section 382”). Under Section 382, an ownership change may limit the amount of NOL, capital loss and R&D credit carry-forwards that can be used annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We conduct a study annually of our ownership changes. Based on the results of our studies, we have determined that we do not have any ownership changes on or prior to December 31, 2017 which would result in limitations of our NOL, capital loss or R&D credit carry-forwards under Section 382.  Uncertain Tax Positions We file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined. The periods subject to examination for those returns are the 1998 through 2017 tax years. The following table provides a reconciliation of our unrecognized tax benefits due to uncertain tax positions for the years ended December 31, 2017 and 2016, respectively (in thousands).     2017 2016  Unrecognized tax benefits – beginning of year $ 1,370 $ 1,370  Gross increases – tax positions in prior period - -  Impact of the Tax Act (443) -  Unrecognized tax benefits – end of year $ 927 $ 1,370   Future changes in the unrecognized tax benefit will have no impact on the effective tax rate so long as we maintain a full valuation allowance.  Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense. We do not have any accrued interest or penalties associated with any unrecognized tax benefits. For the years ended December 31, 2017 and 2016, we did not incur any income tax-related interest income, expense or penalties.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2017
Share-Based Compensation [Abstract]
Share-Based Compensation	10. SHARE-BASED COMPENSATION  The following table presents share-based compensation expense included in our consolidated statements of comprehensive loss for the years ended December 31, 2017 and 2016, respectively (in thousands):    2017 2016  Research and development expense $ 564 $ 630  Selling, general, and administrative expense 1,600 1,580  Total share-based compensation expense $ 2,164 $ 2,210   We did not capitalize any expense related to share-based payments. As of December 31, 2017, there was $1.2 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. That cost is expected to be recognized over a weighted-average period of approximately one year.  Stock Incentive Plans  2011 Long-Term Incentive Equity Plan We adopted a long-term incentive equity plan in September 2011 that, as amended in 2014, 2016 and 2017, provided for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 3.0 million shares of common stock (the “2011 Plan”). The 2011 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted share awards, and other stock based awards. Forfeited and expired options under the 2011 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 150,000 shares in any calendar year. At December 31, 2017, approximately 673,896 shares of common stock were available for future grants under the 2011 Plan.  2008 Equity Incentive Plan We adopted an equity incentive plan in August 2008 (the “2008 Plan”). The 2008 Plan provides for the grant of stock-based awards to employees (excluding named executives), directors and consultants, not to exceed 50,000 shares of common stock. The 2008 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted share awards, and other stock based awards. Forfeited and expired options under the 2008 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 5,000 shares in any calendar year. At December 31, 2017, 15,142 shares of common stock were available for future grants under the 2008 Plan.  2000 Performance Equity Plan We adopted a performance equity plan in July 2000 (the “2000 Plan”). The 2000 Plan provided for the grant of options and other stock awards to employees, directors and consultants, not to exceed 500,000 shares of common stock. The 2000 Plan provided for benefits in the form of incentive and nonqualified stock options, stock appreciation rights, restricted share awards, stock bonuses and various stock benefits or cash. Upon shareholder approval of amendments to our 2011 Long-Term Incentive Equity Plan on June 17, 2014, the 2000 Plan was amended such that no further awards may be granted under this plan.  Restricted Stock Awards RSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested.  Restricted Stock Units RSUs are issued as incentive compensation to executives, employees, and non-employee directors as well as payment for services to third parties. Each RSU represents a right to one share of our common stock, upon vesting. The RSUs are not entitled to voting rights or dividends, if any, until vested. RSUs generally vest over a one to three year period for employee awards, a one year period for non-employee director awards and the life of the related service contract for third-party awards. The fair value of RSUs is generally based on the closing price of our common stock on the date of grant and is amortized to share-based compensation expense over the estimated life of the award, generally the vesting period. In the case of RSUs issued to third parties, the fair value is recognized based on the closing price of our common stock on each vesting date.  RSAs and RSUs The following table presents a summary of RSA and RSU activity under the 2000, 2008, and 2011 Plans (collectively, the “Stock Plans”) as of December 31, 2017 (shares in thousands):      Non-vested Shares  Shares Weighted-Average Grant-Date Fair Value  Non-vested at beginning of year 330 $ 5.16  Granted 669 1.98  Vested (476) 4.18  Forfeited (2) 1.98  Non-vested at end of year 521 $ 1.98   The total fair value of RSAs and RSUs vested under the Stock Plans for the year ended December 31, 2017 is $0.9 million.  Stock Options Stock options are issued as incentive compensation to executives, employees, non-employee directors, and third parties. Stock options are generally granted with exercise prices at or above fair market value of the underlying shares at the date of grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. In the case of option grants to third parties, the fair value is estimated at each interim reporting date until vested. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans.  The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2017 (shares in thousands):     Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 691 $ 14.89  Granted 318 1.97  Exercised - -  Forfeited - -  Expired (2) 6.80  Outstanding at end of year 1,007 10.82 3.68 years $ -  Vested and expected to vest at end of year 671 $ 15.26 2.33 years $ -   The weighted average per share fair value of option shares granted during the years ended December 31, 2017 and 2016 was $1.52 and $1.74 , respectively. The total fair value of option shares vested was $0.2 million for each of the years ended December 31, 2017 and 2016.  The fair value of option grants under the Stock Plans for the years ended December 31, 2017 and 2016, respectively, was estimated using the Black-Scholes option-pricing model with the following assumptions:      Year ended December 31,  2017 2016  Expected option term 1 4 to 6 years 7 years  Expected volatility factor 2 98.0% to 100.8% 97.80%  Risk-free interest rate 3 1.7% to 2.2% 2.3%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. For consultants, the expected term was determined based on the contractual life of the award. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.  We occasionally grant stock options outside the Stock Plans, generally to third parties. At December 31, 2016, we had one option for the purchase of 6,000 shares of common stock outstanding and exercisable at an exercise price of $20.10 . This option expired unexercised in October 2017. At December 31, 2017, there were no outstanding options outside the Stock Plans.  Options by Price Range The options outstanding at December 31, 2017 under all plans have exercise price ranges, weighted average contractual lives, and weighted average exercise prices are as follows (weighted average lives in years and shares in thousands):     Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2017 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2017 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $1.11 - $1.80 66 $ 1.75 5.06 30 $ 1.80 4.88  $1.84 - $5.80 416 2.05 6.41 116 2.17 6.05  $7.50 - $11.80 227 8.98 0.77 227 8.98 0.77  $13.20 - $22.60 46 13.72 2.68 46 13.72 2.68  $23.80 - $38.80 243 28.25 1.58 243 28.25 1.58  $45.10 - $45.10 9 45.10 2.96 9 45.10 2.96  1,007 $ 10.82 3.68 671 $ 15.26 2.33   Upon exercise of options under all plans, we issue new shares of our common stock. For shares issued upon exercise of equity awards granted under the Stock Plans, the shares of common stock are registered. For shares issued upon exercise of non-plan awards, the shares are not registered unless they have been subsequently registered by us on a registration statement. We have had no option exercises for the years ended December 31, 2017 and 2016 .

Stock Authorization And Issuanc

Stock Authorization And Issuance	12 Months Ended
	Dec. 31, 2017
Stock Authorization And Issuance [Abstract]
Stock Authorization And Issuance	11. STOCK AUTHORIZATION AND ISSUANCE Preferred Stock We have 15 million shares of preferred stock authorized for issuance at the direction of the board of directors. On November 17, 2005, our board of directors designated 0.1 million shares of authorized preferred stock as the Series E Preferred Stock in conjunction with its adoption of a Shareholder Protection Rights Agreement (Note 12). As of December 31, 2017, we had no outstanding preferred stock.  Common Stock On July 11, 2017, our shareholders approved an amendment to our articles of incorporation to increase the number of authorized shares of common stock from 20 million to 30 million shares.  Stock Issuances The following table presents a summary of completed equity offerings for the years ended December 31, 2017 and 2016 (in thousands, except for per share amounts):    Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit Net Proceeds (1) Offering as % of Outstanding Common Stock (2)  October - December 2017 Offerings under Common Stock Purchase Agreement 773 $1.29 $ 958 3.6%  August - December 2017 Offerings under At Market Issuance Sales Agreement 2,119 $1.50 $ 2,970 10.2%  February 24, 2017 Offering to a member of our Board of Directors 81 $2.11 $ 170 0.5%  January - March 2017 Offerings under At Market Issuance Sales Agreement 4,072 $2.46 $ 9,581 23.0%  July 7, 2016 Offering sold to an individual investor (3) 1,091 $2.75 $ 2,860 8.5%  January 25, 2016 Offering sold to an in individual investor 455 $2.20 $ 990 4.0%  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs. (2) Calculated on an after-issued basis. (3) Shares are registered under a registration statement that was declared effective August 2, 2016 (File No. 333-212670).  Common Stock Purchase Agreement In October 2017, we entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”). Under the Purchase Agreement, Aspire Capital committed to purchase up to an aggregate of $20 million in shares of our common stock over the 30 -month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, we issued to Aspire Capital 287,500 shares of our common stock as a commitment fee. We filed a registration statement to register the sale of up to 4 million shares of our common stock by Aspire Capital that have been or may be issued under the Purchase Agreement. The registration statement was declared effective November 27, 2017 (File No. 333-221250).  Under the Purchase Agreement, on any trading day selected by us, we have the right, in our sole discretion, to present Aspire Capital with a purchase notice, directing Aspire Capital to purchase up to 150,000 shares of our common stock, provided that the aggregate purchase amount for such shares does not exceed $0.5 million and subject to the maximum aggregate amount of $20 million. The per share purchase price for each purchase notice is equal to the lesser of (i) the lowest sale price of our common stock on the purchase date; or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which we submit a purchase notice to Aspire Capital, we also have the right, in our sole discretion, to present Aspire Capital with a volume-weighted average price (“VWAP”) purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on its principal market on the next trading day, or such lesser amount as we may determine. The purchase price per share pursuant to the VWAP purchase notice is generally 97% of the volume-weighted average price for our common stock traded on its principal market on the VWAP purchase date, subject to terms and limitations of the agreement.  The number of shares that may be issued to Aspire Capital under the Purchase Agreement is limited to that number of shares representing 19.99% of our pre-transaction shares outstanding (the “Exchange Cap”), unless shareholder approval is obtained or unless the average price for shares sold in excess of the Exchange Cap is equal or greater to $1.48 which represents the closing bid price of our common stock at the date we entered into the Purchase Agreement.  At Market Issuance Sales Agreements We filed a shelf registration statement on Form S-3 with the SEC in November 2016 (Registration No. 333-214598) for the offering of various securities, up to $15 million, over a period of up to three years. On December 30, 2016, we entered into an ATM agreement with FBR Capital Markets & Co. (“FBR”) for the sale of up to $10 million in shares of our common stock under the shelf registration statement (the “First ATM”). From January through March 2017, we sold an aggregate of 4.1 million shares of our common stock at an average price of $2.46 per share under the First ATM.  On August 14, 2017, we entered into a new ATM agreement with FBR for the sale of up to approximately $4.4 million in shares of our common stock registered under the shelf registration statement (the “Second ATM”). From August to December 2017, we completed the sale of approximately 2.1 million shares of our common stock at an average price of $1.50 under the Second ATM. We had approximately $1.2 million remaining available for sale under the Second ATM as of December 31, 2017.  Stock for Services For the year ended December 31, 2017, we issued an aggregate of 0.3 million shares of unregistered common stock to two consultants in exchange for an aggregate of approximately $0.4 million in prepaid retainers for executive consulting and other advisory services. We have no registration obligation with respect to these shares.  Common Stock Warrants As of December 31, 2017, we had outstanding warrants for the purchase of up to 0.4 million shares of our common stock. The estimated grant date fair value of these warrants of $0.8 million is included in shareholders’ (deficit) equity in our consolidated balance sheets. The outstanding warrants have an average exercise price of $2.21 per share and a weighted average remaining life of approximately three years. Cash received from warrant exercises for the years ended December 31, 2017 and 2016 was $0 and $0.4 million, respectively.  Our outstanding warrants include a warrant issued to BKI in connection with our secured contingent payable obligation (see Note 8). The BKI warrant is for the purchase up to 350,000 shares of our common stock at an exercise price of $2.00 per share valued at its estimated fair market value of $0.3 million using a discounted Black-Scholes model. The aggregate fair value of the BKI warrant is included in shareholders’ (deficit) equity in the consolidated balance sheets at December 31, 2017 and 2016. The shares underlying the warrants were registered on a registration statement declared effective on August 2, 2016.  Director Stock Purchase On March 26, 2018 three of our directors purchased an aggregate of 0.2 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $0.83 per share. We received proceeds of approximately $0.2 million.

Shareholder Protection Rights A

Shareholder Protection Rights Agreement	12 Months Ended
	Dec. 31, 2017
Shareholder Protection Rights Agreement [Abstract]
Shareholder Protection Rights Agreement	12. SHAREHOLDER PROTECTION RIGHTS AGREEMENT  On November 20, 2015, we amended our Shareholder Protection Rights Agreement (“Rights Agreement”) dated November 21, 2005. The amendment extends the expiration date of the Rights Agreement from November 21, 2015 to November 20, 2020 and decreases the exercise price of the rights to $1 4.50 after giving effect to the one -for-ten reverse stock split that became effective March 30, 2016.  The Rights Agreement provided for the issuance, on November 29, 2005, as a dividend, rights to acquire fractional shares of Series E Preferred Stock. We did not assign any value to the dividend as the value of these rights is not believed to be objectively determinable. The principal objective of the Rights Agreement is to cause someone interested in acquiring us to negotiate with our board of directors (the “Board”) rather than launch an unsolicited or hostile bid. The Rights Agreement subjects a potential acquirer to substantial voting and economic dilution. Each share of common stock issued by ParkerVision will include an attached right.  The rights initially are not exercisable and trade with the common stock of ParkerVision. In the future, the rights may become exchangeable for shares of Series E Preferred Stock with various provisions that may discourage a takeover bid. Additionally, the rights have what are known as “flip-in” and “flip-over” provisions that could make any acquisition of us more costly to the potential acquirer. The rights may separate from the common stock following the acquisition of 15 % or more of the outstanding shares of common stock by an acquiring person. Upon separation, the holder of the rights may exercise their right at an exercise price of $ 14.50 per right (the “Exercise Price”), subject to adjustment and payable in cash. Upon payment of the Exercise Price, the holder of the right will receive from us that number of shares of common stock having an aggregate market price equal to twice the Exercise Price, as adjusted. The Rights Agreement also has a flip over provision allowing the holder to purchase that number of shares of common/voting equity of a successor entity, if we are not the surviving corporation in a business combination, at an aggregate market price equal to twice the Exercise Price. We have the right to substitute for any of our shares of common stock that we are obligated to issue, shares of Series E Preferred Stock at a ratio of one ten-thousandth of a share of Series E Preferred Stock for each share of common stock. The Series E Preferred Stock, if and when issued, will have quarterly cumulative dividend rights payable when and as declared by the Board, liquidation, dissolution and winding up preferences, voting rights and will rank junior to other securities of ParkerVision unless otherwise determined by the Board.  The rights may be redeemed upon approval of the Board at a redemption price of $ 0.01 .

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13. COMMITMENTS AND CONTINGENCIES Lease Commitments The following table presents a summary of our facilities under non-cancelable lease agreements at December 31, 2017:      Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 6/1/2006 7/15/2018 none $ 28   Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13   Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2   Deferred rent is amortized to rent expense over the respective lease terms. In addition to sales tax payable on base rental amounts, certain leases obligate us to pay pro-rated annual operating expenses for the properties. Rent expense for properties, for the years ended December 31, 2017 and 2016 was $0.6 million and $0.5 million, respectively.  Contractual Obligations Future minimum lease payments under all non-cancelable operating leases and capital leases that have initial terms in excess of one year as of December 31, 2017 were as follows (in thousands):     Contractual obligations: 2018 2019 2020 and thereafter Total  Operating leases $ 372 $ 185 $ 535 $ 1,092  Capital leases $ 2 $ 2 $ 1 $ 5   Legal Proceedings From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) and in the Federal Patent Court in Germany in an attempt to invalidate certain of our patent claims. These patent-related proceedings are more fully described below. We have several patent enforcement actions in Germany which has a “loser pay” system whereby the non-prevailing party is responsible for statutory attorney fees and costs. We do not believe it is probable that we will have unfavorable outcomes in any of our German cases and therefore we have not recorded any expenses related to these statutory fees and costs. However, there is at least a reasonable possibility of an unfavorable outcome in any one or more of these matters that could result in expenses in the aggregate that could have a material unfavorable impact on our results of operations as more fully discussed below.  ParkerVision v. Qualcomm and HTC (Middle District of Florida) We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “Qualcomm”), and HTC (HTC Corporation and HTC America, Inc.) (the “Qualcomm Action”) seeking unspecified damages and injunctive relief for infringement of certain of our patents. Certain of the defendants have filed counterclaims against us for non-infringement and invalidity for all patents in the case. A claim construction hearing was held in August 2015 but no ruling on claim construction has been issued by the court. In February 2016, the court granted the parties’ joint motion to stay these proceedings until resolution of the proceedings at the International Trade Commission (“ITC”) as discussed below. In May 2017, we filed a motion to continue the stay of these proceedings pending an appeal of certain PTAB decisions with regard to our U.S. Patent 6,091,940 (“the ‘940 Patent”) as discussed below.  Qualcomm v. ParkerVision (PTAB) In August 2015, Qualcomm filed an aggregate of ten petitions for Inter Partes Review (“IPR”) with the PTAB seeking to invalidate certain claims related to three of the eleven patents originally asserted in our Qualcomm Action. In March 2016, the PTAB issued decisions denying institution of trial for three of the petitions, all of which relate to our U.S. patent 7,039,372 (“the ‘372 Patent”). The remaining petitions, all of which relate to the ‘940 Patent and U.S. patent 7,966,012 (“the ‘012 Patent”) were instituted for trial by the PTAB. In May 2016, the PTAB granted our motion to disclaim the challenged claims of the ‘012 Patent and entered an adverse judgment against us with respect to those claims. In March 2017, the PTAB issued its decisions on the six outstanding IPRs, all of which relate to the ‘940 Patent. The PTAB ruled in our favor on three of the six petitions, ruled in Qualcomm’s favor on two of the six petitions and issued a split decision on the claims covered in the sixth petition. As a result of the PTAB decisions, certain claims of the ‘940 Patent which are the subject of our district court case against Qualcomm and HTC were found to be un-patentable. In May 2017, we filed our notice of appeal of these decisions with the Federal Circuit. Qualcomm also cross-appealed. Briefing is complete and we expect oral arguments to be scheduled in the second or third quarter of 2018.  ParkerVision v. Apple and Qualcomm (ITC) In December 2015, we filed a complaint with the U.S. ITC against Apple, Inc., LG Electronics, Inc., LG Electronics U.S.A., Inc., and LG Electronics MobileComm U.S.A., Inc. (collectively “LG”), Samsung Electronics Co., Ltd., Samsung Electronics America, Inc., and Samsung Semiconductor, Inc. (collectively “Samsung”) and Qualcomm alleging that these companies make, use or sell products that infringe certain of our patent claims and requesting that the ITC bar the defendants from continuing to import and sell infringing products in the U.S. We filed a corresponding patent infringement complaint in the Middle District of Florida against these same defendants. In January 2016, the ITC instituted an investigation based on our complaint. In July 2016, we entered into a confidential patent license and settlement agreement with Samsung and, as a result, Samsung was removed from the ITC action. In January 2017, we dismissed three of the four patents from the case in order to simplify the investigation. On March 10, 2017, the administrative law judge issued a ruling on a pre-trial motion that precluded us from presenting key evidence in our case. As a result, on March 13, 2017, we filed a motion to terminate the proceedings at the ITC. On April 28, 2017, the ITC granted our motion to withdraw from the ITC proceedings.  ParkerVision v. Apple and Qualcomm (Middle District of Florida) In connection with our complaint filed at the ITC in December 2015 as discussed above, we filed a corresponding patent infringement complaint in the Middle District of Florida against Apple, LG, Samsung and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of the proceedings at the ITC and in July 2016, Samsung was removed from the district court action as a result of a patent license and settlement agreement. Following the termination of the ITC proceedings in March 2017, we filed a motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case (see ParkerVision v. LG below). Also in July 2017, Qualcomm filed a motion to change venue to the southern district of California and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings. The parties are awaiting a revised court schedule for the proceedings, including the claim construction hearing which was originally scheduled for January 2018.  ParkerVision v. LG (District of New Jersey) In July 2017, we filed a patent infringement complaint in the district of New Jersey against LG for the alleged infringement of the same patents previously asserted against LG in the middle district of Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in the middle district of Florida and re-file in New Jersey as a result of a recent Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case.  ParkerVision v. LG Electronics (Munich, Germany) In June 2016, we filed a complaint in Munich District Court against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc. (“LGE”) seeking damages and injunctive relief for the alleged infringement of the German part of our European patent 1 206 831 (“the ‘831 Patent). A hearing in this case was held in November 2016 at which time the court concluded that certain LGE products using Qualcomm RF circuitry infringe our patent. The final decision in this case is stayed pending resolution of the corresponding nullity, or validity, action filed by Qualcomm in the German Federal Patent Court in Munich (see Qualcomm v. ParkerVision below). If we do not prevail in this case, we may be subject to a claim for reimbursement of statutory attorney’s fees and costs estimated at approximately $0.06 million for which we have posted a bond. If we prevail in the validity action filed by Qualcomm, the district court will then issue its final infringement decision which, if favorable, will likely include an injunction blocking the sale and importation of LGE products in Germany.  ParkerVision v. Apple (Munich, Germany) In October 2016, we filed a complaint in Munich District Court against Apple, Inc., Apple Distribution International, and Apple Retail Germany B.V. & Co. KG (collectively “Apple”) seeking damages and injunctive relief for the alleged infringement of the ‘831 Patent (the “Apple I” case). In February 2017, we amended our complaint adding the infringement of a second German patent and alleging infringement by Apple devices that incorporate an Intel transceiver chip. The Munich Regional Court bifurcated the new claims into a second case (the “Apple II” case). A hearing was held in May 2017 in the Apple I case. In June 2017, the court deferred its ruling pending the decision from the German Federal Patent Court in the validity action filed by Qualcomm (see Qualcomm v. ParkerVision below ). We anticipate the decision in this case will mirror that in the ParkerVision v. LG case in Germany discussed above. If we do not prevail in this case, we may be subject to a claim for reimbursement of statutory attorney’s fees and costs estimated at approximately $0.1 million. We expect that we will post a bond to cover this exposure in 2018.  Qualcomm v. ParkerVision (Federal Patent Court in Germany) In August 2016, Qualcomm filed a validity action in Federal Patent Court in Germany against the ’831 Patent. The outcome of this validity action impacts our German patent infringement cases against LGE and Apple as discussed above. An oral hearing is scheduled in this case on October 17, 2018 and a decision is expected to be handed down at that time. The Federal Patent Court can uphold the ‘831 Patent, declare the ‘831 Patent to be invalid, or, alternatively, can uphold the ‘831 Patent with amended, narrowed claims that we have proposed. If the ‘831 Patent is declared invalid, we would be subject to a claim for reimbursement of statutory attorney fees and costs of approximately $0.2 million.  ParkerVision v. Apple (Munich, Germany)- the Apple II case The Apple II case seeks damages and injunctive relief for the alleged infringement of the German part of our European patent 1 135 853 (“the ‘853 Patent). A hearing was held in November 2017. Subsequent to the hearing, the court requested that we supplement certain elements of the infringement claims against Apple devices. The court also denied Apple’s request that we provide a bond covering any possible claims for reimbursement of statutory attorney’s fees and costs; however, in order to expedite proceedings, we have agreed to pay a bond of approximately $0.1 million in April 2018, which is our estimated maximum exposure in this case. We expect a second oral hearing in this case to take place in the second quarter of 2018.  Intel v. ParkerVision (Federal Patent Court in Germany) In August 2017, Intel filed a nullity action in German Federal Patent Court claiming invalidity of the ‘853 Patent that is the subject of the Apple II case. If the ‘853 Patent is declared invalid, we would be subject to a claim for reimbursement of statutory attorney fees and costs of approximately $0.2 million. We intend to vigorously defend the validity of our patent. No dates have yet been set in this nullity action.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transaction	14. RELATED PARTY TRANSACTIONS  We paid approximately $0.03 million and $0.4 million in 2017 and 2016, respectively, for patent-related legal services to the law firm of Sterne, Kessler, Goldstein & Fox, PLLC (“SKGF”), of which Robert Sterne, one of our directors since September 2006, is a partner. In February 2016, we entered into an agreement with SKGF to convert $0.8 million in outstanding unpaid fees to an unsecured note payable. In December 2017, we entered into a note modification agreement with SKGF to extend the maturity date of the note from December 31, 2017 to March 31, 2020 (see Note 8). We paid SKGF interest on the note payable of approximately $0.07 million a nd $0.06 million in 2017 and 2016, respectively.  In February 2017, Mr. Paul Rosenbaum, one of our directors since December 2016, purchased 80,510 shares of our common stock in an unregistered sale of equity securities at a purchase price of $2.11 per share (see Note 11). 

Concentrations Of Credit Risk

Concentrations Of Credit Risk	12 Months Ended
	Dec. 31, 2017
Concentrations Of Credit Risk [Abstract]
Concentration Of Credit Risk	15. CONCENTRATIONS OF CREDIT RISK  Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents, restricted cash equivalents, and our available for sale securities. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may exceed the balance insured by the F.D.I.C. Restricted cash equivalents are held in accounts with brokerage institutions and consist of short-term money market funds. Our available-for-sale securities are held in accounts with brokerage institutions and consist of mutual funds invested primarily in short-term municipal securities.  We maintain our investments with what management believes to be quality financial institutions and while we limit the amount of credit exposure to any one institution, we could be subject to credit risks from concentration of investments in a single fund as well as credit risks arising from adverse conditions in the financial markets as a whole.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	16. FAIR VALUE MEASUREMENTS  ASC 820, “Fair Value Measures” establishes a fair value hierarchy that prioritizes the inputs to valuation methods used to measure fair value. The three levels of the fair value hierarchy are as follows:  · Level 1: Quoted prices for identical assets or liabilities in active markets which we can access · Level 2: Observable inputs other than those described in Level 1 · Level 3: Unobservable inputs  The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 and 2016, segregated by classification within the fair value hierarchy (in thousands):     Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2017:  Assets:  Available-for-sale securities $ 26 $ 26 $ - $ -  Restricted cash equivalents 1,000 1,000 - -  Liabilities:  Secured contingent payment obligation 15,896 - - 15,896    December 31, 2016:  Assets:  Available-for-sale securities $ 14 $ 14 $ - $ -  Restricted cash equivalents 911 911 - -  Liabilities:  Secured contingent payment obligation 14,185 - - 14,185   For the years ended December 31, 2017 and 2016, respectively, we had no transfers of assets or liabilities between the levels of the hierarchy. We determine the fair value of our available-for-sale securities and restricted cash equivalents using a market approach based on quoted prices in active markets (Level 1 inputs).  In 2016, we recognized a secured contingent payment obligation upon our receipt of proceeds from BKI for funding of certain patent-related actions (see Note 8). The fair value of the contingent payment obligation at December 31, 2017 was estimated at $15.9 million using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. The contingent payment obligation does not have a fixed duration; however our cash flow projections assume a duration ranging from 2018 through 2021. The assumed cash outflows range from $0 to $34 million and the cash flow scenarios have probabilities of 0% to 30% . We used a risk-adjusted discount rate of approximately 16% , based on a five year risk-free rate of approximately 2% as adjusted by 8% for credit risk and 6% for litigation inherent risk. Changes in any of these Level 3 inputs could result in a higher or lower fair value measurement. For example, a decrease in the risk-adjusted discount rate from 16% to 8% would result in an increase in the fair value of approximately $3 million. Refer to Note 8 for a reconciliation of our secured contingent payment obligation measured at estimated fair value for the years ended December 31, 2017 and 2016.

Schedule II - Valuation And Qua

Schedule II - Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation And Qualifying Accounts	 SCHE DULE II  PARKERVISION, INC. AND SUBSIDIARY  VALUATION AND QUALIFYING ACCOUNTS  FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016      Valuation Allowance for Income Taxes Balance at Beginning of Year Provision Write-Offs Balance at End of Year  Year ended December 31, 2016 122,152 8,145 (1,072) 129,225  Year ended December 31, 2017 129,225 (34,346) (464) 94,415  

Summary Of Significant Accoun24

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles. Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH after elimination of all intercompany transactions and accounts.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash, Cash Equivalents, and Restricted Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased. Restricted cash equivalents represent money market investments that are restricted for specific use in payment of legal fees and expenses related to certain of our patent infringement actions. The restricted money market investments have weighted average maturities of three months or less when purchased and are recorded at fair value. We have determined that the fair value of our restricted money market investments fall within Level 1 in the fair value hierarchy (see Note 16). 
Available-for-Sale Securities	Available-for-Sale Securities A vailable-for-sale securities are intended to be held for indefinite periods of time and are not intended to be held to maturity. These securities are recorded at fair value and any unrealized holding gains and losses, net of the related tax effect, are excluded from earnings and are reported as a separate component of accumulated other comprehensive loss until realized. The tax effect of our unrealized holding gains and losses is zero for each of the years ended December 31, 2017 and 2016 due to the existence of a full valuation allowance. Our available-for-sale securities at December 31, 2017 and 2016 consisted of mutual funds that invest primarily in short-term municipal securities with an average effective maturity of one year or less. All dividends and realized gains are recognized as other income as earned and immediately reinvested. The Company has determined that the fair value of its available-for-sale securities fall within Level 1 in the fair value hierarchy (See Note 16).
Inventory	Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change. For the year ended December 31, 2017, we recognized a write down of excess inventory of our PV5870 ICs of approximately $0.1 million. 
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:      Manufacturing and office equipment 5 -7 years  Tooling 3 years  Leasehold improvements Remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets. 
Intangible Assets	Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. We estimate the economic lives of other intangible assets, including licenses, based on estimated technological obsolescence, to be two to five years, which is generally shorter than the contractual lives. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.
Secured Contingent Payment Obligation	Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 16). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation”.
Leases	Leases Our facilities are leased under operating leases. For those leases that contain rent escalations or rent concessions, we record the total rent payable during the lease term on a straight-line basis over the term of the lease with the difference between the rents paid and the straight-line rent recorded as a deferred rent liability in the accompanying consolidated balance sheets.  In February 2016, the FASB issued ASU 2016-02 “Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption of ASU 2016-02, beginning period balances for the earliest period presented must be adjusted to reflect the re-measurement of lease assets and liabilities. We anticipate adoption of ASU 2016-02 as of January 1, 2019. We have identified all existing operating and financing leases and are in the process of determining the present value of existing lease assets and liabilities under the new guidance. We are also currently formalizing processes and controls to identify, classify and measure new leases in accordance with ASU 2016-02. The impact of ASU 2016-02 on our consolidated financial statements is currently being evaluated.
Revenue Recognition	Revenue Recognition We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes, sales of products, and engineering services. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when there is persuasive evidence of an arrangement, title has transferred, the amounts are fixed and determinable and the collectability is reasonably assured.   Revenue from the sale of products is recognized at the time of shipment to the customer or when the other criteria for revenue recognition are met, if later. Unearned revenue at December 31, 2017 and 2016 consists of product inventory held by a distributor. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when earned. We recognize revenues upon execution of a patent license and settlement agreement by both parties provided that the amounts are fixed and determinable, there are no significant undelivered obligations and collectability is reasonably assured. We do not recognize any revenue prior to the execution of an agreement as there is no reliable basis on which we can estimate the amounts related to the elements of the arrangement, or assess collectability. In addition, we do not recognize as revenue any consideration in the agreement that is contingent upon the occurrence of future events until such time that those future events occur.  In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. ASU 2015-14, “Revenue from Contracts with Customers (Topic 606)”, issued in August 2015, defers adoption of ASU 2014-09 to annual reporting periods beginning after December 15, 2017. We do not currently expect the adoption of ASU 2014-09 to have a material effect on our consolidated financial statements .
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs related to product sales were approximately $5,000 , or 5% of product revenue, for the year ended December 31, 2017. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Advertising Expense	Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.4 million and $0 for the years ended December 31, 2017 and 2016, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation. 
Accounting for Share-Based Compensation	Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 10. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The new standard is effective for annual periods beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. The adoption of this guidance is not expected to have a material effect on our consolidated financial statements.
Income Taxes	Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease to 21% effective for tax years beginning after December 31, 2017. 
Loss per Common Share	Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  Options and warrants to purchase 1.4 million and 1.1 million shares of common stock were outstanding at December 31, 2017 and, 2016, respectively. In addition, unvested RSUs representing 0.5 million and 0.3 million shares of common stock were outstanding at December 31, 2017 and 2016, respectively. These options, warrants and RSUs were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Summary Of Significant Accoun25

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Schedule Of Property And Equipment Useful Lives	   Manufacturing and office equipment 5 -7 years  Tooling 3 years  Leasehold improvements Remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years 

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventories [Abstract]
Schedule Of Inventories	   2017 2016  Raw materials $ 573 $ -  Work-in-process - 126  Finished goods 452 44  $ 1,025 $ 170  

Prepaid Expenses And Other (Tab

Prepaid Expenses And Other (Tables)	12 Months Ended
	Dec. 31, 2017
Prepaid Expenses And Other [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   2017 2016  Prepaid services $ 328 $ 459  Prepaid licenses, software tools and support 404 41  Prepaid inventory and production tooling 121 -  Prepaid insurance 54 108  Other prepaid expenses and current assets 104 77  $ 1,011 $ 685  

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	   2017 2016  Equipment and software, including equipment purchased under capital leases of $297 and $292 at December 31, 2017 and 2016, respectively $ 6,556 $ 7,777  Tooling - 94  Leasehold improvements 786 926  Furniture and fixtures 185 502  7,527 9,299  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $206 and $156 at December 31, 2017 and 2016, respectively (7,151) (9,030)  $ 376 $ 269  

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Intangible Assets [Abstract]
Schedule Of Intangible Assets	   2017  Gross Carrying Amount Accumulated Amortization Net Value  Patents and copyrights $ 19,324 $ 14,248 $ 5,076  Licenses - - -  $ 19,324 $ 14,248 $ 5,076       2016  Gross Carrying Amount Accumulated Amortization Net Value  Patents and copyrights $ 19,499 $ 13,231 $ 6,268  Licenses 574 574 -  $ 20,073 $ 13,805 $ 6,268  
Schedule Of Future Amortization Expense	   2018 $ 1,062  2019 771  2020 546  2021 468  2022 417  2023 and thereafter 1,812  Total $ 5,076  

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Long-Term Debt [Abstract]
Schedule Of Notes Payable	    Description Interest Rate Interest Payable Maturity Date 2017 2016  Note payable to a related party 8% Monthly March 31, 2020 $ 825 $ 825  Less current maturities 294 825  Long-term note payable $ 531 $ -  
Summary Of Aggregate Maturities	   2018 $ 294  2019 420  2020 111  Total $ 825  
Reconciliation Of Secured Contingent Obligation At Fair Value	      2017 2016  Secured contingent payment obligation, beginning of year $ 14,185 $ -  Proceeds from contingent payment obligation 1 1,000 12,665  Repayment - (3,340)  Change in fair value 711 4,860  Secured contingent payment obligation, end of year $ 15,896 $ 14,185  1 Proceeds in 2016 are net of $0.3 million which represents the estimated fair market value of warrants issued in connection with the agreement (see Note 11).

Income Taxes And Tax Status (Ta

Income Taxes And Tax Status (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes And Tax Status [Abstract]
Schedule Of Effective Income Tax Rate Reconciliation	   2017 2016  Tax benefit at statutory rate $ (6,548) $ (7,313)  State tax benefit (674) (753)  Impact of the Tax Act 41,646 -  (Decrease) increase in valuation allowance (34,346) 8,145  Research and development credit (129) (97)  Other 51 18  $ - $ -  
Schedule Of Deferred Tax Assets And Liabilities	   2017 2016  Gross deferred tax assets:  Net operating loss carry-forward $ 82,168 $ 115,296  Research and development credit 8,051 7,922  Stock compensation 1,248 1,885  Patents and other 1,427 2,119  Contingent payment obligation 1,409 1,823  Fixed assets 25 78  Accrued liabilities 49 54  Deferred rent 20 19  Charitable contributions 7 11  Deferred revenue 5 7  Capital loss carry-forward 3 8  Warranty reserve 2 -  Bad debt expense 1 2  Inventory - 1  94,415 129,225  Less valuation allowance (94,415) (129,225)  Net deferred tax asset $ - $ -  
Schedule Of Unrecognized Tax Benefits Roll Forward	   2017 2016  Unrecognized tax benefits – beginning of year $ 1,370 $ 1,370  Gross increases – tax positions in prior period - -  Impact of the Tax Act (443) -  Unrecognized tax benefits – end of year $ 927 $ 1,370  

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share-Based Compensation Expense Included In Statements Of Operations	   2017 2016  Research and development expense $ 564 $ 630  Selling, general, and administrative expense 1,600 1,580  Total share-based compensation expense $ 2,164 $ 2,210  
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Options Activity	   Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 691 $ 14.89  Granted 318 1.97  Exercised - -  Forfeited - -  Expired (2) 6.80  Outstanding at end of year 1,007 10.82 3.68 years $ -  Vested and expected to vest at end of year 671 $ 15.26 2.33 years $ -  
Summary Of Valuation Assumptions	    Year ended December 31,  2017 2016  Expected option term 1 4 to 6 years 7 years  Expected volatility factor 2 98.0% to 100.8% 97.80%  Risk-free interest rate 3 1.7% to 2.2% 2.3%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. For consultants, the expected term was determined based on the contractual life of the award. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.
Summary Of Options And Warrants By Exercise Price Range	   Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2017 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2017 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $1.11 - $1.80 66 $ 1.75 5.06 30 $ 1.80 4.88  $1.84 - $5.80 416 2.05 6.41 116 2.17 6.05  $7.50 - $11.80 227 8.98 0.77 227 8.98 0.77  $13.20 - $22.60 46 13.72 2.68 46 13.72 2.68  $23.80 - $38.80 243 28.25 1.58 243 28.25 1.58  $45.10 - $45.10 9 45.10 2.96 9 45.10 2.96  1,007 $ 10.82 3.68 671 $ 15.26 2.33  
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Restricted Stock Activity	   Non-vested Shares  Shares Weighted-Average Grant-Date Fair Value  Non-vested at beginning of year 330 $ 5.16  Granted 669 1.98  Vested (476) 4.18  Forfeited (2) 1.98  Non-vested at end of year 521 $ 1.98  

Stock Authorization And Issua33

Stock Authorization And Issuance (Tables)	12 Months Ended
	Dec. 31, 2017
Stock Authorization And Issuance [Abstract]
Summary Of Equity Offerings	   Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit Net Proceeds (1) Offering as % of Outstanding Common Stock (2)  October - December 2017 Offerings under Common Stock Purchase Agreement 773 $1.29 $ 958 3.6%  August - December 2017 Offerings under At Market Issuance Sales Agreement 2,119 $1.50 $ 2,970 10.2%  February 24, 2017 Offering to a member of our Board of Directors 81 $2.11 $ 170 0.5%  January - March 2017 Offerings under At Market Issuance Sales Agreement 4,072 $2.46 $ 9,581 23.0%  July 7, 2016 Offering sold to an individual investor (3) 1,091 $2.75 $ 2,860 8.5%  January 25, 2016 Offering sold to an in individual investor 455 $2.20 $ 990 4.0%  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs. (2) Calculated on an after-issued basis. (3) Shares are registered under a registration statement that was declared effective August 2, 2016 (File No. 333-212670).

Commitments And Contingencies (

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies [Abstract]
Summary Of Facilities Under Lease Agreements	   Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 6/1/2006 7/15/2018 none $ 28   Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13   Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2  
Schedule Of Future Minimum Lease Payments For Capital Leases And Operating Leases	   Contractual obligations: 2018 2019 2020 and thereafter Total  Operating leases $ 372 $ 185 $ 535 $ 1,092  Capital leases $ 2 $ 2 $ 1 $ 5  

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Schedule Of Assets Measured At Fair Value On A Recurring Basis	   Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2017:  Assets:  Available-for-sale securities $ 26 $ 26 $ - $ -  Restricted cash equivalents 1,000 1,000 - -  Liabilities:  Secured contingent payment obligation 15,896 - - 15,896    December 31, 2016:  Assets:  Available-for-sale securities $ 14 $ 14 $ - $ -  Restricted cash equivalents 911 911 - -  Liabilities:  Secured contingent payment obligation 14,185 - - 14,185  

Liquidity And Going Concern (De

Liquidity And Going Concern (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Liquidity And Going Concern [Abstract]
Net loss	$ (19,259)	$ (21,509)
Net cash used in operating activities	(14,060)	(14,364)
Accumulated deficit	(371,423)	(352,164)
Net working capital	200
Cash, cash equivalents and available for sale securities	400
Restricted cash equivalents	$ 1,000	$ 911

Summary Of Significant Accoun37

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Available-for-sale Securities, gross unrealized gain		$ 0	$ 0
Writedown of obsolete inventory		$ 125,000
Options and warrants outstanding		1.4	1.1
Shipping and handling costs		$ 5,000
Advertising expenses		$ 400,000	$ 0
Corporate tax rate		34.00%	34.00%	34.00%
Scenario, Plan [Member]
Significant Accounting Policies [Line Items]
Corporate tax rate	21.00%
Sales Revenue, Product Line [Member] | Product Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Percentage of product revenue		5.00%
Patents And Copyrights [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life		15 years
Patents And Copyrights [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life		20 years
Licenses [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life		2 years
Licenses [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life		5 years
Restricted Stock Units (RSUs) [Member]
Significant Accounting Policies [Line Items]
Unvested, Shares		0.5	0.3

Summary Of Significant Accoun38

Summary Of Significant Accounting Policies (Schedule Of Property And Equipment Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2017
Tooling [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life	Remaining life of lease
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Maximum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Maximum [Member] | Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Minimum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Minimum [Member] | Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventories [Abstract]
Raw materials	$ 573
Work-in-process		$ 126
Finished goods	452	44
Total inventories	$ 1,025	$ 170

Prepaid Expenses And Other (Det

Prepaid Expenses And Other (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expenses And Other [Abstract]
Prepaid services	$ 328	$ 459
Prepaid licenses, software tools and support	404	41
Prepaid inventory and production costs	121
Prepaid Insurance	54	108
Other prepaid expenses and current assets	104	77
Prepaid expense and other current assets	$ 1,011	$ 685

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property And Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 150	$ 170
Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 50	$ 60
Minimum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	1 year
Maximum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	3 years

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment	$ 7,527	$ 9,299
Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $206 and $156 at December 31, 2017 and 2016, respectively	(7,151)	(9,030)
Property, Plant and Equipment, Net, Total	376	269
Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6,556	7,777
Capital leases	297	292
Accumulated depreciation for capital leases	206	156
Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		94
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	786	926
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 185	$ 502

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets [Abstract]
Amortization expense	$ 1.2	$ 1.2

Intangible Assets (Schedule Of

Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,324	$ 20,073
Accumulated Amortization	14,248	13,805
Net Book Value	5,076	6,268
Patents And Copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	19,324	19,499
Accumulated Amortization	14,248	13,231
Net Book Value	$ 5,076	6,268
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		574
Accumulated Amortization		$ 574

Intangible Assets (Schedule O45

Intangible Assets (Schedule Of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets [Abstract]
2,018	$ 1,062
2,019	771
2,020	546
2,021	468
2,022	417
2023 and thereafter	1,812
Net Book Value	$ 5,076	$ 6,268

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($)	12 Months Ended				24 Months Ended
	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2017	Feb. 29, 2016
Debt Instrument [Line Items]
Notes payable	$ 531,000				$ 531,000
Proceeds from contingent payment obligation	$ 1,000,000	[1]	12,665,000	[1]	14,000,000
Percentage of proceeds payment	100.00%
Note Payable To A Related Party [Member]
Debt Instrument [Line Items]
Maturity date	Mar. 31, 2020
Note payable to a related party	$ 825,000		825,000		825,000
Notes payable	$ 531,000				531,000
Note Payable To A Related Party [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Debt						$ 800,000
Maturity date	Mar. 31, 2020
Note Payable To A Related Party [Member] | Unsecured Note [Member] | Risk-Adjusted Discount Rate [Member]
Debt Instrument [Line Items]
Fair value of note payable	$ 700,000				$ 700,000
[1]	20172016Secured contingent payment obligation, beginning of year$ 14,185$ -Proceeds from contingent payment obligation 1 1,000 12,665Repayment - (3,340)Change in fair value 711 4,860Secured contingent payment obligation, end of year$ 15,896$ 14,185Proceeds in 2016 are net of $0.3 million which represents the estimated fair market value of warrants issued in connection with the agreement (see Note 11).

Long-Term Debt (Schedule Of Not

Long-Term Debt (Schedule Of Notes Payable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Less current maturities	$ 294	$ 825
Long term note payable	$ 531
Note Payable To A Related Party [Member]
Interest rate	8.00%
Interest Payable	Monthly
Maturity Date	Mar. 31, 2020
Note payable to a related party	$ 825	825
Less current maturities	294	825
Long term note payable	$ 531

Long-Term Debt (Summary Of Aggr

Long-Term Debt (Summary Of Aggregate Maturities) (Details) $ in Thousands	Dec. 31, 2017USD ($)
Long-Term Debt [Abstract]
2,018	$ 294
2,019	420
2,020	111
Total	$ 825

Long-Term Debt (Reconciliation

Long-Term Debt (Reconciliation Of Secured Contingent Obligation At Fair Value) (Details) - USD ($) $ in Thousands	12 Months Ended				24 Months Ended
	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2017
Long-Term Debt [Abstract]
Secured contingent payment obligation, beginning of year	$ 14,185
Proceeds from contingent payment obligation	1,000	[1]	$ 12,665	[1]	$ 14,000
Repayment			(3,340)
Change in fair value	711		4,860
Secured contingent payment obligation, end of year	15,896		$ 14,185		$ 15,896
Fair value of warrants issued	$ 300
[1]	20172016Secured contingent payment obligation, beginning of year$ 14,185$ -Proceeds from contingent payment obligation 1 1,000 12,665Repayment - (3,340)Change in fair value 711 4,860Secured contingent payment obligation, end of year$ 15,896$ 14,185Proceeds in 2016 are net of $0.3 million which represents the estimated fair market value of warrants issued in connection with the agreement (see Note 11).

Income Taxes And Tax Status (Na

Income Taxes And Tax Status (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
Foreign income tax expense			$ 660,000
Current tax provision or benefit		0	0	$ 0
Deferred tax provision or benefit		$ 0	$ 0
Corporate tax rate		34.00%	34.00%	34.00%
Operating loss carryforwards		$ 328,400,000
Unrecognized tax benefits		927,000	$ 1,370,000	$ 1,370,000
Accrued interest or penalties		0	0
Income tax-related interest income, expense or penalties		0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, Amount		8,100,000
Capital Loss Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, Amount		$ 10,000
Minimum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration		Dec. 31, 2018
Period subject to IRS examination		1,998
Maximum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration		Dec. 31, 2036
Period subject to IRS examination		2,017
Scenario, Plan [Member]
Tax Credit Carryforward [Line Items]
Corporate tax rate	21.00%

Income Taxes And Tax Status (Sc

Income Taxes And Tax Status (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes And Tax Status [Abstract]
Tax benefit at statutory rate	$ 41,646
State tax benefit	(6,548)	(7,313)
Impact of the Tax Act	(674)	(753)
(Decrease) increase in valuation allowance	(34,346)	8,145
Research and development credit	(129)	(97)
Other	51	18
Income Tax Expense (Benefit), Total

Income Taxes And Tax Status (52

Income Taxes And Tax Status (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Taxes And Tax Status [Abstract]
Net operating loss carry-forward	$ 82,168	$ 115,296
Research and development credit	8,051	7,922
Stock compensation	1,248	1,885
Patents and other	1,427	2,119
Contingent payment obligation	1,409	1,823
Fixed assets	25	78
Accrued liabilities	49	54
Deferred rent	20	19
Charitable contributions	7	11
Deferred revenue	5	7
Capital loss carry-forward	3	8
Warranty reserve	2
Bad debt expense	1	2
Inventory		1
Deferred tax assets, gross	94,415	129,225
Less valuation allowance	(94,415)	(129,225)
Net deferred tax asset

Income Taxes And Tax Status (53

Income Taxes And Tax Status (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes And Tax Status [Abstract]
Unrecognized tax benefits, beginning of year	$ 1,370	$ 1,370
Gross increases – tax positions in prior period
Impact of the Tax Act	(443)
Unrecognized tax benefits, end of year	$ 927	$ 1,370

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, net of estimated forfeitures	$ 1,200,000
Expected weighted average period to recognize the compensation cost, in years	1 year
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	50,000
Number of shares available for grant	15,142
Maximum number of shares per employee	5,000
2000 Performance Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	500,000
2011 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	3,000,000
Number of shares available for grant	673,896
Maximum number of shares per employee	150,000
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested fair value	$ 900,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of option shares granted	$ 1.52	$ 1.74
Fair market value of vested shares	$ 200,000
Common stock outstanding	1,007,000	691,000
Exercise price	$ 10.82	$ 14.89
Intrinsic value of options exercised	$ 0	$ 0
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Non Employee [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Third Parties [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding	0	6,000
Exercise price		$ 20.10

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Share-Based Compensation Expense Included In Statements Of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,164	$ 2,210
Research And Development Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	564	630
Selling, General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 1,600	$ 1,580

Share-Based Compensation (Summa

Share-Based Compensation (Summary Of RSU Activity) (Details) - Restricted Stock Award And Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at beginning of year, Shares | shares	330
Granted, Shares | shares	669
Vested, Shares | shares	(476)
Forfeited, Shares | shares	(2)
Non-vested at end of year, Shares | shares	521
Non-vested at beginning of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 5.16
Granted, Weighted Average Grant Date Fair Value | $ / shares	1.98
Vested, Weighted Average Grant Date Fair Value | $ / shares	4.18
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	1.98
Non-vested at end of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 1.98

Share-Based Compensation (Sum57

Share-Based Compensation (Summary Of Option Activity) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Shares, Beginning of year | shares	691
Granted, Shares | shares	318
Exercised, Shares | shares
Forfeited, Shares | shares
Expired, Shares | shares	(2)
Outstanding, Shares, End of year | shares	1,007
Outstanding, Weighted Average Exercise Price, Beginning of year | $ / shares	$ 14.89
Granted, Weighted Average Exercise Price | $ / shares	1.97
Exercised, Weighted Average Exercise Price | $ / shares
Forfeited, Weighted Average Exercise Price | $ / shares
Expired, Weighted Average Exercise Price | $ / shares	6.80
Outstanding, Weighted Average Exercise Price, End of year | $ / shares	$ 10.82
Outstanding, Weighted Average Remaining Contractual Term	3 years 8 months 5 days
Outstanding, Aggregate Intrinsic Value | $
Vested and expected to vest at end of year, shares | shares	671
Vested and expected to vest at end of year, weighted average exercise price | $ / shares	$ 15.26
Vested and expected to vest at end of year, weighted average remaining contractual term	2 years 3 months 29 days
Vested and expected to vest at end of year, aggregate intrinsic value | $

Share-Based Compensation (Sum58

Share-Based Compensation (Summary Of Valuation Assumptions) (Details) - Stock Options [Member]		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term			7 years
Expected volatility factor	[1]		97.80%
Risk-free interest rate	[2]		2.30%
Expected annual dividend yield		0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term		4 years
Expected volatility factor		98.00%
Risk-free interest rate		1.70%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term		6 years
Expected volatility factor		100.80%
Risk-free interest rate		2.20%
[1]	The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant.
[2]	The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.

Share-Based Compensation (Sum59

Share-Based Compensation (Summary Of Options And Warrants By Exercise Price Range) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Options Outstanding
Number Outstanding | shares	1,007
Wtd. Avg. Exercise Price	$ 10.82
Wtd. Avg. Remaining Contractual Life	3 years 8 months 5 days
Options Vested
Number Exercisable | shares	671
Wtd. Avg. Exercise Price	$ 15.26
Wtd. Avg. Remaining Contractual Life	2 years 3 months 29 days
$1.11 - $1.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 1.11
Exercise price maximum	$ 1.80
Options Outstanding
Number Outstanding | shares	66
Wtd. Avg. Exercise Price	$ 1.75
Wtd. Avg. Remaining Contractual Life	5 years 22 days
Options Vested
Number Exercisable | shares	30
Wtd. Avg. Exercise Price	$ 1.80
Wtd. Avg. Remaining Contractual Life	4 years 10 months 17 days
$1.84 - $5.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 1.84
Exercise price maximum	$ 5.80
Options Outstanding
Number Outstanding | shares	416
Wtd. Avg. Exercise Price	$ 2.05
Wtd. Avg. Remaining Contractual Life	6 years 4 months 28 days
Options Vested
Number Exercisable | shares	116
Wtd. Avg. Exercise Price	$ 2.17
Wtd. Avg. Remaining Contractual Life	6 years 18 days
$7.50 - $11.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 7.50
Exercise price maximum	$ 11.80
Options Outstanding
Number Outstanding | shares	227
Wtd. Avg. Exercise Price	$ 8.98
Wtd. Avg. Remaining Contractual Life	9 months 7 days
Options Vested
Number Exercisable | shares	227
Wtd. Avg. Exercise Price	$ 8.98
Wtd. Avg. Remaining Contractual Life	9 months 7 days
$13.20 - $22.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 13.20
Exercise price maximum	$ 22.60
Options Outstanding
Number Outstanding | shares	46
Wtd. Avg. Exercise Price	$ 13.72
Wtd. Avg. Remaining Contractual Life	2 years 8 months 5 days
Options Vested
Number Exercisable | shares	46
Wtd. Avg. Exercise Price	$ 13.72
Wtd. Avg. Remaining Contractual Life	2 years 8 months 5 days
$23.80 - $38.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 23.80
Exercise price maximum	$ 38.80
Options Outstanding
Number Outstanding | shares	243
Wtd. Avg. Exercise Price	$ 28.25
Wtd. Avg. Remaining Contractual Life	1 year 6 months 29 days
Options Vested
Number Exercisable | shares	243
Wtd. Avg. Exercise Price	$ 28.25
Wtd. Avg. Remaining Contractual Life	1 year 6 months 29 days
$45.10 - $45.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 45.10
Exercise price maximum	$ 45.10
Options Outstanding
Number Outstanding | shares	9
Wtd. Avg. Exercise Price	$ 45.10
Wtd. Avg. Remaining Contractual Life	2 years 11 months 16 days
Options Vested
Number Exercisable | shares	9
Wtd. Avg. Exercise Price	$ 45.10
Wtd. Avg. Remaining Contractual Life	2 years 11 months 16 days

Stock Authorization And Issua60

Stock Authorization And Issuance (Narrative) (Details) $ / shares in Units, $ in Thousands	Mar. 26, 2018USD ($)item$ / sharesshares	Nov. 14, 2017USD ($)$ / sharesshares	Oct. 17, 2017USD ($)shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)shares	Nov. 30, 2017shares	Oct. 31, 2017USD ($)shares	Aug. 14, 2017USD ($)	Jul. 11, 2017shares	Jul. 10, 2017shares	Nov. 17, 2005shares
Stock Authorization And Issuance [Line Items]
Preferred Stock, Shares authorized				15,000,000	15,000,000							100,000
Preferred Stock, Shares outstanding				0	0
Common stock, shares authorized				30,000,000	30,000,000	30,000,000				30,000,000	20,000,000
Shelf, duration		3 years	30 months
Sale of common stock under commitment fee			287,500
Sale of common stock, number of shares		4,100,000		2,100,000
Sale of common stock | $					$ 13,679	$ 4,136
Sale of stock price per share | $ / shares		$ 2.46		$ 1.50	$ 1.50
Purchase notice			30.00%
Purchase price per share, VWAP			97.00%
Amount remaining under the ATM | $				$ 1,200	$ 1,200
Shares of common stock issued upon exercise of warrants					400,000
Estimated fair market value | $				$ 800	$ 800
Exercise price per warrant | $ / shares				$ 2.21	$ 2.21
Warrants expiration period					3 years
Proceeds from warrants exercised | $					$ 0	400
Issuance of stock to consultants, shares					300,000
Issuance of stocks to consultants | $					$ 400
Exchange cap | $ / shares					$ 1.48
BKI Warrant [Member]
Stock Authorization And Issuance [Line Items]
Shares of common stock issued upon exercise of warrants					350,000
Estimated fair market value | $				$ 300	$ 300
Exercise price per warrant | $ / shares				$ 2	$ 2
Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock | $					$ 73	$ 16
2008 Equity Incentive Plan [Member]
Stock Authorization And Issuance [Line Items]
Number of shares authorized				50,000	50,000
2000 Performance Equity Plan [Member]
Stock Authorization And Issuance [Line Items]
Number of shares authorized				500,000	500,000
2011 Long Term Incentive Equity Plan [Member]
Stock Authorization And Issuance [Line Items]
Number of shares authorized				3,000,000	3,000,000
Maximum [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $		$ 15,000	$ 20,000					$ 500	$ 4,400
Aggregate offering shares							4,000,000	150,000
Maximum [Member] | Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $		$ 10,000
Subsequent Event [Member] | Director [Member]
Stock Authorization And Issuance [Line Items]
Number of directors | item	3
Subsequent Event [Member] | Director [Member] | Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock, number of shares	200,000
Sale of common stock | $	$ 200
Sale of stock price per share | $ / shares	$ 0.83

Stock Authorization And Issua61

Stock Authorization And Issuance (Summary Of Equity Offerings) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 13,679	$ 4,136
Net Proceeds		0	$ 400
Offerings Under Common Stock Purchase Agreement [Member] | October - December 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 773
Average Price per Share/Unit		$ 1.29
Net Proceeds	[1]	$ 958
Offering as % of Outstanding Common Stock	[2]	3.60%
Offerings Under At Market Issuance Sales Agreement [Member] | August - December 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 2,119
Average Price per Share/Unit		$ 1.50
Net Proceeds	[1]	$ 2,970
Offering as % of Outstanding Common Stock	[2]	10.20%
Offerings Under At Market Issuance Sales Agreement [Member] | January - March 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 4,072
Average Price per Share/Unit		$ 2.46
Net Proceeds	[1]	$ 9,581
Offering as % of Outstanding Common Stock	[2]	23.00%
Offering To A Member Of Our Board Of Directors [Member] | February 24, 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 81
Average Price per Share/Unit		$ 2.11
Net Proceeds	[1]	$ 170
Offering as % of Outstanding Common Stock	[2]	0.50%
Offering Sold To An In Individual Investor [Member] | July 7, 2016 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 1,091
Average Price per Share/Unit		$ 2.75
Net Proceeds	[1]	$ 2,860
Offering as % of Outstanding Common Stock	[2]	8.50%
Offering Sold To An In Individual Investor [Member] | January 25, 2016 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 455
Average Price per Share/Unit		$ 2.20
Net Proceeds	[1]	$ 990
Offering as % of Outstanding Common Stock	[2]	4.00%
[1]	DateTransaction# of Common Shares/ Units SoldAverage Price per Share/UnitNet Proceeds (1)Offering as % of Outstanding Common Stock (2)October - December 2017Offerings under Common Stock Purchase Agreement 773$1.29$ 958 3.6%August - December 2017Offerings under At Market Issuance Sales Agreement2,119$1.50$ 2,970 10.2%February 24, 2017Offering to a member of our Board of Directors81$2.11$ 1700.5%January - March 2017Offerings under At Market Issuance Sales Agreement4,072$2.46$ 9,58123.0%July 7, 2016Offering sold to an individual investor (3)1,091$2.75$ 2,860 8.5%January 25, 2016Offering sold to an in individual investor455$2.20$ 990 4.0%After deduction of applicable underwriters' discounts, placement agent fees, and other offering costs.
[2]	Calculated on an after-issued basis. Shares are registered under a registration statement that was declared effective August 2, 2016 (File No. 333-212670).

Shareholder Protection Rights62

Shareholder Protection Rights Agreement (Details)	Mar. 30, 2016$ / shares	Dec. 31, 2017$ / shares
Acquisition of outstanding shares		15.00%
Exercise Price	$ 14.50	$ 14.50
Redemption price		$ 0.01
Post reserve split ratio	0.1
Series E Preferred Stock [Member]
Post reserve split ratio		0.0001

Commitments And Contingencies63

Commitments And Contingencies (Narractive) (Details) $ in Thousands

Mar. 10, 2017item

Mar. 07, 2017item

Aug. 27, 2015item

Mar. 31, 2018item

Feb. 28, 2017item

Jan. 31, 2017item

Dec. 31, 2015item

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Apr. 30, 2018USD ($)

Aug. 31, 2017USD ($)

Jun. 30, 2017USD ($)

Jun. 30, 2016USD ($)

Commitments and Contingencies [Line Items]

Rent expense | $

$ 600

$ 500

ParkerVision vs. Qualcomm, Inc. [Member]

Commitments and Contingencies [Line Items]

Number of petitions

10

Number of additional patents allegedly infringed upon

3

Number of patents found infringed upon

3

Number of patents allegedly infringed upon

11

Number of patents found not infringed upon

2

Number of patents with split decision

1

ParkerVision v. LG Electronics [Member]

Commitments and Contingencies [Line Items]

Estimated attorney's fees and costs | $

$ 60

ParkerVision V. Apple And Qualcomm (ITC) [Member]

Commitments and Contingencies [Line Items]

Number of patents dismissed

1

3

ParkerVision V. Apple [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Estimated attorney's fees and costs | $

$ 100

ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Qualcomm v. ParkerVision (Federal Patent Court in Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated attorney's fees and costs | $

$ 200

Intel v. ParkerVision (Federal Patent Court in Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated attorney's fees and costs | $

$ 200

Subsequent Event [Member] | ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of patents with motion to dismiss

3

Subsequent Event [Member] | ParkerVision v. Apple (Munich, Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated attorney's fees and costs | $

$ 100

Commitments And Contingencies64

Commitments And Contingencies (Summary Of Facilities Under Lease Agreements) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Corporate Office [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jun. 1, 2006
Lease End Date	Jul. 15, 2018
Straight line monthly rental payment	$ 28
Wireless Design Facility [Member] | Lake Mary Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Nov. 30, 2022
Renewal options remaining	36 months
Straight line monthly rental payment	$ 13
Warehouse And Production Facility [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Jul. 31, 2020
Straight line monthly rental payment	$ 2

Commitments And Contingencies65

Commitments And Contingencies (Schedule Of Future Minimum Lease Payments For Capital Leases And Operating Leases) (Details) $ in Thousands	Dec. 31, 2017USD ($)
Commitments And Contingencies [Abstract]
Operating leases 2018	$ 372
Operating leases 2019	185
Operating leases 2020	535
Operating Leases Total	1,092
Capital Leases 2018	2
Capital Leases 2019	2
Capital Leases 2020	1
Capital Leases, Total	$ 5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Nov. 14, 2017	Feb. 28, 2017	Feb. 29, 2016
Related Party Transaction [Line Items]
Sale of common stock, number of shares	21,222,000	13,183,000
Sale of stock price per share	$ 1.50		$ 2.46
Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid for patent-related legal services	$ 30,000	$ 400,000
Director [Member] | Mr. Paul Rosenbaum [Member]
Related Party Transaction [Line Items]
Sale of common stock, number of shares				80,510
Sale of stock price per share				$ 2.11
Note Payable To A Related Party [Member]
Related Party Transaction [Line Items]
Maturity date	Mar. 31, 2020
Note Payable To A Related Party [Member] | Unsecured Note [Member]
Related Party Transaction [Line Items]
Debt					$ 800,000
Maturity date	Mar. 31, 2020
Interest paid	$ 70,000	$ 60,000

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset transfers	$ 0	$ 0
Liabilities transfers	0	0
Change in fair value	$ 711,000	$ 4,860,000
Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	8.00%	16.00%
Risk free term	5 years
Risk free rate	2.00%
Credit risk	8.00%
litigation inherent risk	6.00%
Change in fair value	$ 3,000,000
Minimum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 0
Contingent obligation, probability	0.00%
Maximum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 34,000,000
Contingent obligation, probability	30.00%
Probability-Eeighted Income Approach [Member] | Unsecured Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of note payable	$ 15,900,000

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 15,896	$ 14,185
Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	26	14
Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,000	911
Quoted Prices In Active Markets (Level 1) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Quoted Prices In Active Markets (Level 1) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	26	14
Quoted Prices In Active Markets (Level 1) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,000	911
Significant Other Observable Inputs (Level 2) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Other Observable Inputs (Level 2) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Other Observable Inputs (Level 2) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Unobservable Inputs (Level 3) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	15,896	14,185
Significant Unobservable Inputs (Level 3) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Unobservable Inputs (Level 3) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets

Schedule II - Valuation And Q69

Schedule II - Valuation And Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Balance at beginning of year	$ 129,225	$ 122,152
Provision	(34,346)	8,145
Write offs	(464)	(1,072)
Balance at end of year	$ 94,415	$ 129,225